US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · T2DM (Type 2 Diabetes Mellitus) · Type 2 Diabetes Mellitus · ORMP
Oramed Pharmaceuticals
ORAMED PHARMACEUTICALS INC.
Oramed Pharmaceuticals drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
20 Mamilla Avenue, 3rd Floor, Jerusalem, 9414904, IL HQ
2006 Founded
16 Employees
Public company Type
ORMP · NYSE Ticker
Company details
- Status
- Public
- HQ
- 20 Mamilla Avenue, 3rd Floor, Jerusalem, 9414904, IL
- Founded
- 2006
- Employees
- 16
- Programs
- 14
- Drugs
- 8
- Patents
- 10
Oramed Pharmaceuticals pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Oramed Pharmaceuticals drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
Development asset linked to Oramed Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Oramed Pharmaceuticals in public FDA and regional records.
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Oramed Pharmaceuticals's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Oramed Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Oramed Pharmaceuticals in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Oramed Pharmaceuticals in public FDA and regional records.